The assay is currently under development and assesses hundreds of genes across all variant classes and immune-oncology biomarkers
DNA technology company Illumina is due to release TruSight Oncology 500 v2 (TSO 500 v2), a new version of its cancer research essay to enable comprehensive genomic profiling (CGP).
“There are different needs for biomarker profiling, and Illumina has introduced a continuum of solutions to address varying levels of need," said vice president of clinical solutions at Illumina Traci Pawlowski.
The TSO 500 v2 assesses hundreds of genes across all variant classes and immune-oncology biomarkers. It identifies rare genetic biomarkers and fusion biomarkers, and this is done in a single assay from one sample to facilitate therapy selection research.
The aim is to increase turnaround and reduce hands-on time and allow for automation methods with flexible batch sizes. The automation of data analysis is one key feature supported by Dragen secondary analysis and Insights, or Velsera’s Clinical Genomics Workspace.
The Myriad Genomic Instability Score determines homologous recombination deficiency status.
Although TSO 500 v2 comprises 50% less packaging and 70% fewer tubes, it offers broad platform compatibility and improved coverage of difficult genomic regions.
The assay is currently under development and is expected to be released mid-2025.
